Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Alginate-chitosan PEC scaffolds: A useful tool for soft tissues cell therapy.

Bushkalova R, Farno M, Tenailleau C, Duployer B, Cussac D, Parini A, Sallerin B, Girod Fullana S.

Int J Pharm. 2019 Nov 25;571:118692. doi: 10.1016/j.ijpharm.2019.118692. Epub 2019 Sep 12.

PMID:
31520678
2.

Bell-shaped agonist activation of 5-HT1A receptor-coupled Gαi3 G-proteins: Receptor density-dependent switch in receptor signaling.

Newman-Tancredi A, Cussac D, Ormière AM, Lestienne F, Varney MA, Martel JC.

Cell Signal. 2019 Nov;63:109383. doi: 10.1016/j.cellsig.2019.109383. Epub 2019 Jul 31.

PMID:
31376526
3.

Aging induces cardiac mesenchymal stromal cell senescence and promotes endothelial cell fate of the CD90 + subset.

Martini H, Iacovoni JS, Maggiorani D, Dutaur M, Marsal DJ, Roncalli J, Itier R, Dambrin C, Pizzinat N, Mialet-Perez J, Cussac D, Parini A, Lefevre L, Douin-Echinard V.

Aging Cell. 2019 Oct;18(5):e13015. doi: 10.1111/acel.13015. Epub 2019 Jul 29.

4.

Innovative Bioluminescence Resonance Energy Transfer Assay Reveals Differential Agonist-Induced D2 Receptor Intracellular Trafficking and Arrestin-3 Recruitment.

De Vries L, Finana F, Cathala C, Ronsin B, Cussac D.

Mol Pharmacol. 2019 Sep;96(3):308-319. doi: 10.1124/mol.119.115998. Epub 2019 Jul 2.

PMID:
31266815
5.

Multimodal gadolinium oxysulfide nanoparticles: a versatile contrast agent for mesenchymal stem cell labeling.

Santelli J, Lechevallier S, Baaziz H, Vincent M, Martinez C, Mauricot R, Parini A, Verelst M, Cussac D.

Nanoscale. 2018 Sep 13;10(35):16775-16786. doi: 10.1039/c8nr03263g.

PMID:
30156241
6.

Distinctive in vitro signal transduction profile of NLX-112, a potent and efficacious serotonin 5-HT1A receptor agonist.

Newman-Tancredi A, Martel JC, Cosi C, Heusler P, Lestienne F, Varney MA, Cussac D.

J Pharm Pharmacol. 2017 Sep;69(9):1178-1190. doi: 10.1111/jphp.12762. Epub 2017 Jun 14.

PMID:
28612503
7.

Contribution of muscarinic receptors to in vitro and in vivo effects of Ruscus extract.

Rauly-Lestienne I, Heusler P, Cussac D, Lantoine-Adam F, de Almeida Cyrino FZG, Bouskela E.

Microvasc Res. 2017 Nov;114:1-11. doi: 10.1016/j.mvr.2017.05.005. Epub 2017 May 19.

PMID:
28529172
8.

Elaboration and evaluation of alginate foam scaffolds for soft tissue engineering.

Ceccaldi C, Bushkalova R, Cussac D, Duployer B, Tenailleau C, Bourin P, Parini A, Sallerin B, Girod Fullana S.

Int J Pharm. 2017 May 30;524(1-2):433-442. doi: 10.1016/j.ijpharm.2017.02.060. Epub 2017 Mar 6.

PMID:
28279740
9.

Pharmacological evaluation of a series of smoothened antagonists in signaling pathways and after topical application in a depilated mouse model.

Lauressergues E, Heusler P, Lestienne F, Troulier D, Rauly-Lestienne I, Tourette A, Ailhaud MC, Cathala C, Tardif S, Denais-Laliève D, Calmettes MT, Degryse AD, Dumoulin A, De Vries L, Cussac D.

Pharmacol Res Perspect. 2016 Mar 4;4(2):e00214. doi: 10.1002/prp2.214. eCollection 2016 Apr.

10.

Intramyocardial transplantation of mesenchymal stromal cells for chronic myocardial ischemia and impaired left ventricular function: Results of the MESAMI 1 pilot trial.

Guijarro D, Lebrin M, Lairez O, Bourin P, Piriou N, Pozzo J, Lande G, Berry M, Le Tourneau T, Cussac D, Sensebe L, Gross F, Lamirault G, Huynh A, Manrique A, Ruidavet JB, Elbaz M, Trochu JN, Parini A, Kramer S, Galinier M, Lemarchand P, Roncalli J.

Int J Cardiol. 2016 Apr 15;209:258-65. doi: 10.1016/j.ijcard.2016.02.016. Epub 2016 Feb 2.

PMID:
26901787
11.

[Ageing: a matter of heart?].

Mialet-Perez J, Douin-Echinard V, Cussac D, Bril A, Parini A.

Med Sci (Paris). 2015 Nov;31(11):1006-13. doi: 10.1051/medsci/20153111015. Epub 2015 Nov 17. Review. French.

12.
13.

Characterization of V0162, a new long-acting antagonist at human M3 muscarinic acetylcholine receptors.

Heusler P, Cussac D, Naline E, Tardif S, Clerc T, Devillier P.

Pharmacol Res. 2015 Oct;100:117-26. doi: 10.1016/j.phrs.2015.07.033. Epub 2015 Aug 1.

PMID:
26241178
14.

Consequences of combining siRNA-mediated DNA methyltransferase 1 depletion with 5-aza-2'-deoxycytidine in human leukemic KG1 cells.

Vispé S, Deroide A, Davoine E, Desjobert C, Lestienne F, Fournier L, Novosad N, Bréand S, Besse J, Busato F, Tost J, De Vries L, Cussac D, Riond J, Arimondo PB.

Oncotarget. 2015 Jun 20;6(17):15265-82.

15.

Potencies and unblocking kinetic properties of antagonists at recombinant human NMDA receptors in a Xenopus oocytes model.

Heusler P, Tourette A, Cussac D.

Naunyn Schmiedebergs Arch Pharmacol. 2015 May;388(5):509-16. doi: 10.1007/s00210-015-1085-6. Epub 2015 Jan 22.

PMID:
25604077
16.

Sphingosine kinase 1 expressed by endothelial colony-forming cells has a critical role in their revascularization activity.

Poitevin S, Cussac D, Leroyer AS, Albinet V, Sarlon-Bartoli G, Guillet B, Hubert L, Andrieu-Abadie N, Couderc B, Parini A, Dignat-George F, Sabatier F.

Cardiovasc Res. 2014 Jul 1;103(1):121-30. doi: 10.1093/cvr/cvu104. Epub 2014 Apr 17.

PMID:
24743591
17.

Cardiac fibroblasts regulate sympathetic nerve sprouting and neurocardiac synapse stability.

Mias C, Coatrieux C, Denis C, Genet G, Seguelas MH, Laplace N, Rouzaud-Laborde C, Calise D, Parini A, Cussac D, Pathak A, Sénard JM, Galés C.

PLoS One. 2013 Nov 14;8(11):e79068. doi: 10.1371/journal.pone.0079068. eCollection 2013.

18.

Evaluation of polyelectrolyte complex-based scaffolds for mesenchymal stem cell therapy in cardiac ischemia treatment.

Ceccaldi C, Bushkalova R, Alfarano C, Lairez O, Calise D, Bourin P, Frugier C, Rouzaud-Laborde C, Cussac D, Parini A, Sallerin B, Fullana SG.

Acta Biomater. 2014 Feb;10(2):901-11. doi: 10.1016/j.actbio.2013.10.027. Epub 2013 Nov 5.

PMID:
24211733
19.

Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety.

Auclair AL, Martel JC, Assié MB, Bardin L, Heusler P, Cussac D, Marien M, Newman-Tancredi A, O'Connor JA, Depoortère R.

Neuropharmacology. 2013 Jul;70:338-47. doi: 10.1016/j.neuropharm.2013.02.024. Epub 2013 Mar 13.

20.

Alginate scaffolds for mesenchymal stem cell cardiac therapy: influence of alginate composition.

Ceccaldi C, Fullana SG, Alfarano C, Lairez O, Calise D, Cussac D, Parini A, Sallerin B.

Cell Transplant. 2012;21(9):1969-84. doi: 10.3727/096368912X647252. Epub 2012 Jul 5.

PMID:
22776769
21.

μ-Opioid and 5-HT1A receptors heterodimerize and show signalling crosstalk via G protein and MAP-kinase pathways.

Cussac D, Rauly-Lestienne I, Heusler P, Finana F, Cathala C, Bernois S, De Vries L.

Cell Signal. 2012 Aug;24(8):1648-57. doi: 10.1016/j.cellsig.2012.04.010. Epub 2012 Apr 25.

PMID:
22560877
22.

Intraparenchymal injection of bone marrow mesenchymal stem cells reduces kidney fibrosis after ischemia-reperfusion in cyclosporine-immunosuppressed rats.

Alfarano C, Roubeix C, Chaaya R, Ceccaldi C, Calise D, Mias C, Cussac D, Bascands JL, Parini A.

Cell Transplant. 2012;21(9):2009-19. doi: 10.3727/096368912X640448. Epub 2012 Apr 17.

PMID:
22525800
23.

S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.

Millan MJ, Mannoury la Cour C, Chanrion B, Dupuis DS, Di Cara B, Audinot V, Cussac D, Newman-Tancredi A, Kamal M, Boutin JA, Jockers R, Marin P, Bockaert J, Muller O, Dekeyne A, Lavielle G.

J Pharmacol Exp Ther. 2012 Mar;340(3):750-64. doi: 10.1124/jpet.111.187468. Epub 2011 Dec 16.

PMID:
22178752
24.

Does endoplasmic reticulum stress participate in APD-induced hepatic metabolic dysregulation?

Lauressergues E, Bert E, Duriez P, Hum D, Majd Z, Staels B, Cussac D.

Neuropharmacology. 2012 Feb;62(2):784-96. doi: 10.1016/j.neuropharm.2011.08.048. Epub 2011 Sep 10.

PMID:
21924277
25.

The clozapine metabolite N-desmethylclozapine displays variable activity in diverse functional assays at human dopamine D₂ and serotonin 5-HT₁A receptors.

Heusler P, Bruins Slot L, Tourette A, Tardif S, Cussac D.

Eur J Pharmacol. 2011 Nov 1;669(1-3):51-8. doi: 10.1016/j.ejphar.2011.07.031. Epub 2011 Aug 5.

PMID:
21835172
26.

Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver.

Lauressergues E, Martin F, Helleboid A, Bouchaert E, Cussac D, Bordet R, Hum D, Luc G, Majd Z, Staels B, Duriez P.

Naunyn Schmiedebergs Arch Pharmacol. 2011 Apr;383(4):423-36. doi: 10.1007/s00210-010-0597-3. Epub 2011 Feb 19.

PMID:
21336545
27.

Rigid analogues of the α2-adrenergic blocker atipamezole: small changes, big consequences.

Vacher B, Funes P, Chopin P, Cussac D, Heusler P, Tourette A, Marien M.

J Med Chem. 2010 Oct 14;53(19):6986-95. doi: 10.1021/jm1006269.

PMID:
20809632
28.

[(3)H]-F13640, a novel, selective and high-efficacy serotonin 5-HT(1A) receptor agonist radioligand.

Heusler P, Palmier C, Tardif S, Bernois S, Colpaert FC, Cussac D.

Naunyn Schmiedebergs Arch Pharmacol. 2010 Oct;382(4):321-30. doi: 10.1007/s00210-010-0551-4. Epub 2010 Aug 27.

PMID:
20799027
29.

Competitive interaction of 5-HT(1A) receptors with G-protein subtypes in CHO cells demonstrated by RNA interference.

Rauly-Lestienne I, Lestienne F, Ailhaud MC, Binesse J, Newman-Tancredi A, Cussac D.

Cell Signal. 2011 Jan;23(1):58-64. doi: 10.1016/j.cellsig.2010.08.002. Epub 2010 Aug 17.

PMID:
20727408
30.

Evaluation of alginate microspheres for mesenchymal stem cell engraftment on solid organ.

Trouche E, Girod Fullana S, Mias C, Ceccaldi C, Tortosa F, Seguelas MH, Calise D, Parini A, Cussac D, Sallerin B.

Cell Transplant. 2010;19(12):1623-33. doi: 10.3727/096368910X514297. Epub 2010 Aug 17.

PMID:
20719065
31.

Actions of the prototypical 5-HT1A receptor agonist 8-OH-DPAT at human alpha2-adrenoceptors: (+)8-OH-DPAT, but not (-)8-OH-DPAT is an alpha2B subtype preferential agonist.

Heusler P, Rauly-Lestienne I, Tourette A, Tardif S, Ailhaud MC, Croville G, Cussac D.

Eur J Pharmacol. 2010 Aug 25;640(1-3):8-14. doi: 10.1016/j.ejphar.2010.04.034. Epub 2010 May 7.

PMID:
20450907
32.

Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes.

Lauressergues E, Staels B, Valeille K, Majd Z, Hum DW, Duriez P, Cussac D.

Naunyn Schmiedebergs Arch Pharmacol. 2010 May;381(5):427-39. doi: 10.1007/s00210-010-0499-4. Epub 2010 Mar 24.

PMID:
20333360
33.

Characterization of monoamine oxidases in mesenchymal stem cells: role in hydrogen peroxide generation and serotonin-dependent apoptosis.

Trouche E, Mias C, Seguelas MH, Ordener C, Cussac D, Parini A.

Stem Cells Dev. 2010 Oct;19(10):1571-8. doi: 10.1089/scd.2009.0353.

PMID:
20073575
34.

Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA.

Vispé S, DeVries L, Créancier L, Besse J, Bréand S, Hobson DJ, Svejstrup JQ, Annereau JP, Cussac D, Dumontet C, Guilbaud N, Barret JM, Bailly C.

Mol Cancer Ther. 2009 Oct;8(10):2780-90. doi: 10.1158/1535-7163.MCT-09-0549. Epub 2009 Oct 6.

35.

Discovery of novel protease activated receptors 1 antagonists with potent antithrombotic activity in vivo.

Perez M, Lamothe M, Maraval C, Mirabel E, Loubat C, Planty B, Horn C, Michaux J, Marrot S, Letienne R, Pignier C, Bocquet A, Nadal-Wollbold F, Cussac D, de Vries L, Le Grand B.

J Med Chem. 2009 Oct 8;52(19):5826-36. doi: 10.1021/jm900553j.

PMID:
19791800
36.

Cellular BRET assay suggests a conformational rearrangement of preformed TrkB/Shc complexes following BDNF-dependent activation.

De Vries L, Finana F, Cachoux F, Vacher B, Sokoloff P, Cussac D.

Cell Signal. 2010 Jan;22(1):158-65. doi: 10.1016/j.cellsig.2009.09.027. Epub 2009 Sep 22.

PMID:
19781635
37.

F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.

Bruins Slot LA, Lestienne F, Grevoz-Barret C, Newman-Tancredi A, Cussac D.

Eur J Pharmacol. 2009 Oct 12;620(1-3):27-35. doi: 10.1016/j.ejphar.2009.08.019. Epub 2009 Aug 18.

PMID:
19695244
38.

Mutant 5-hydroxytryptamine 1A receptor D116A is a receptor activated solely by synthetic ligands with a rich pharmacology.

Cussac D, Palmier C, Finana F, De Vries L, Tardif S, Léger C, Bernois S, Heusler P.

J Pharmacol Exp Ther. 2009 Oct;331(1):222-33. doi: 10.1124/jpet.109.156307. Epub 2009 Jul 15.

PMID:
19605522
39.

Mesenchymal stem cells promote matrix metalloproteinase secretion by cardiac fibroblasts and reduce cardiac ventricular fibrosis after myocardial infarction.

Mias C, Lairez O, Trouche E, Roncalli J, Calise D, Seguelas MH, Ordener C, Piercecchi-Marti MD, Auge N, Salvayre AN, Bourin P, Parini A, Cussac D.

Stem Cells. 2009 Nov;27(11):2734-43. doi: 10.1002/stem.169.

40.

5-HT1A receptors are involved in the effects of xaliproden on G-protein activation, neurotransmitter release and nociception.

Martel JC, Assié MB, Bardin L, Depoortère R, Cussac D, Newman-Tancredi A.

Br J Pharmacol. 2009 Sep;158(1):232-42. doi: 10.1111/j.1476-5381.2009.00249.x. Epub 2009 Jun 5.

41.

Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist.

Newman-Tancredi A, Martel JC, Assié MB, Buritova J, Lauressergues E, Cosi C, Heusler P, Bruins Slot L, Colpaert FC, Vacher B, Cussac D.

Br J Pharmacol. 2009 Jan;156(2):338-53. doi: 10.1111/j.1476-5381.2008.00001.x. Epub 2009 Jan 12.

42.

Region-specific changes in 5-HT1A agonist-induced Extracellular signal-Regulated Kinases 1/2 phosphorylation in rat brain: a quantitative ELISA study.

Buritova J, Berrichon G, Cathala C, Colpaert F, Cussac D.

Neuropharmacology. 2009 Feb;56(2):350-61. doi: 10.1016/j.neuropharm.2008.09.004. Epub 2008 Sep 17.

PMID:
18809418
43.

Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells.

Cussac D, Boutet-Robinet E, Ailhaud MC, Newman-Tancredi A, Martel JC, Danty N, Rauly-Lestienne I.

Eur J Pharmacol. 2008 Oct 10;594(1-3):32-8. doi: 10.1016/j.ejphar.2008.07.040. Epub 2008 Jul 30.

PMID:
18703043
44.

Activation of G proteins and extracellular signal-regulated kinase 1/2 phosphorylation via human dopamine D4.4 receptors: differential pathway-dependent potencies of receptor agonists.

Heusler P, Bruins Slot L, Rauly-Lestienne I, Palmier C, Tardif S, Tourette A, Ailhaud MC, Cussac D.

Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):87-99. doi: 10.1007/s00210-008-0333-4. Epub 2008 Aug 6.

PMID:
18682919
45.

Ex vivo pretreatment with melatonin improves survival, proangiogenic/mitogenic activity, and efficiency of mesenchymal stem cells injected into ischemic kidney.

Mias C, Trouche E, Seguelas MH, Calcagno F, Dignat-George F, Sabatier F, Piercecchi-Marti MD, Daniel L, Bianchi P, Calise D, Bourin P, Parini A, Cussac D.

Stem Cells. 2008 Jul;26(7):1749-57. doi: 10.1634/stemcells.2007-1000. Epub 2008 May 8.

46.

Protease-activated receptor-1 mediates thrombin-induced persistent sodium current in human cardiomyocytes.

Pinet C, Algalarrondo V, Sablayrolles S, Le Grand B, Pignier C, Cussac D, Perez M, Hatem SN, Coulombe A.

Mol Pharmacol. 2008 Jun;73(6):1622-31. doi: 10.1124/mol.107.043182. Epub 2008 Mar 6.

PMID:
18326052
47.

Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.

Heusler P, Newman-Tancredi A, Loock T, Cussac D.

Eur J Pharmacol. 2008 Feb 26;581(1-2):37-46. doi: 10.1016/j.ejphar.2007.11.046. Epub 2007 Nov 28.

PMID:
18190908
48.

S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors.

Millan MJ, Mannoury la Cour C, Novi F, Maggio R, Audinot V, Newman-Tancredi A, Cussac D, Pasteau V, Boutin JA, Dubuffet T, Lavielle G.

J Pharmacol Exp Ther. 2008 Feb;324(2):587-99. Epub 2007 Nov 16.

PMID:
18024789
49.

Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells.

Newman-Tancredi A, Heusler P, Martel JC, Ormière AM, Leduc N, Cussac D.

Int J Neuropsychopharmacol. 2008 May;11(3):293-307. Epub 2007 Sep 26.

PMID:
17897483
50.

Direct protective effects of poly-unsaturated fatty acids, DHA and EPA, against activation of cardiac late sodium current: a mechanism for ischemia selectivity.

Pignier C, Revenaz C, Rauly-Lestienne I, Cussac D, Delhon A, Gardette J, Le Grand B.

Basic Res Cardiol. 2007 Nov;102(6):553-64. Epub 2007 Sep 24.

PMID:
17891522

Supplemental Content

Loading ...
Support Center